184 related articles for article (PubMed ID: 20696631)
1. Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.
Reuter S; Braken P; Jensen B; Sierra-Aragon S; Oette M; Balduin M; Kaiser R; Häussinger D
Eur J Med Res; 2010 Jun; 15(6):231-7. PubMed ID: 20696631
[TBL] [Abstract][Full Text] [Related]
2. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
Willig JH; Wilkins SA; Tamhane A; Nevin CR; Mugavero MJ; Raper JL; Napolitano LA; Saag MS
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):105-11. PubMed ID: 22881368
[TBL] [Abstract][Full Text] [Related]
5. Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.
Sierra S; Dybowski JN; Pironti A; Heider D; Güney L; Thielen A; Reuter S; Esser S; Fätkenheuer G; Lengauer T; Hoffmann D; Pfister H; Jensen B; Kaiser R
PLoS One; 2015; 10(5):e0125502. PubMed ID: 25970632
[TBL] [Abstract][Full Text] [Related]
6. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
Gonzalez-Serna A; McGovern RA; Harrigan PR; Vidal F; Poon AF; Ferrando-Martinez S; Abad MA; Genebat M; Leal M; Ruiz-Mateos E
Antimicrob Agents Chemother; 2012 Mar; 56(3):1202-7. PubMed ID: 22143533
[TBL] [Abstract][Full Text] [Related]
8. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
[TBL] [Abstract][Full Text] [Related]
9. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
McGovern RA; Thielen A; Portsmouth S; Mo T; Dong W; Woods CK; Zhong X; Brumme CJ; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):279-86. PubMed ID: 23095934
[TBL] [Abstract][Full Text] [Related]
10. The maraviroc expanded access program - safety and efficacy data from an open-label study.
Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
12. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc: a review of its use in HIV infection and beyond.
Woollard SM; Kanmogne GD
Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
[TBL] [Abstract][Full Text] [Related]
15. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Swenson LC; Chui CK; Brumme CJ; Chan D; Woods CK; Mo T; Dong W; Chapman D; Lewis M; Demarest JF; James I; Portsmouth S; Goodrich J; Heera J; Valdez H; Harrigan PR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6122-30. PubMed ID: 24080655
[TBL] [Abstract][Full Text] [Related]
16. Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.
Cavarelli M; Mainetti L; Pignataro AR; Bigoloni A; Tolazzi M; Galli A; Nozza S; Castagna A; Sampaolo M; Boeri E; Scarlatti G
AIDS Res Hum Retroviruses; 2014 Dec; 30(12):1243-50. PubMed ID: 25275490
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
18. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Recordon-Pinson P; Raymond S; Bellecave P; Marcelin AG; Soulie C; Descamps D; Calvez V; Harrigan PR; Fleury H; Izopet J; Masquelier B;
Antimicrob Agents Chemother; 2013 Feb; 57(2):930-5. PubMed ID: 23208718
[TBL] [Abstract][Full Text] [Related]
20. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.
Kühne FC; Chancellor J; Mollon P; Myers DE; Louie M; Powderly WG
HIV Clin Trials; 2010; 11(2):80-99. PubMed ID: 20542845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
